Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 11 - 12 save search
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
SRRK 4 | $13.85 -0.72% -0.72% 710K
|
Health Technology
|
| O: -0.35%
H: 3.45%
C: 2.09%
treatment solid tumors phase 1 therapy trial
Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma
Published: 2021-11-12 (Crawled : 22:00) - biospace.com/
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 4.47%
H: 0.0%
C: 0.0%
treatment phase 1 renal positive phase 1b trial phase 2b cell carcinoma
Complement 3 Glomerulopathy (C3G) in 7MM - Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, Current & Forecasted Market Sizes (2018-2030)
Published: 2021-11-12 (Crawled : 16:00) - prnewswire.com
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: 0.0%
treatment drug
Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day
Published: 2021-11-12 (Crawled : 15:00) - prnewswire.com
LTRN | $5.42 -6.07% -6.46% 240K
|
Health Technology
|
| O: -3.14%
H: 0.0%
C: 0.0%
treatment potential cancer drug pancreatic
Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research
Published: 2021-11-12 (Crawled : 15:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
treatment lung cancer positive results cancer research trial trial results
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
AKRO | $20.76 1.22% 1.2% 790K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
treatment phase 2 nash phase 2b
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment solid tumors potential therapy drug clearance t-cell
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment liver
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency
Published: 2021-11-12 (Crawled : 11:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
diabetes treatment europe approval
Citrus Flavonoid Hesperidin And Arthritis Treatment
Published: 2021-11-12 (Crawled : 03:00) - limoneira.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.87%
H: 0.2%
C: 0.2%
LMNR 4 | $19.57 1.29% 1.28% 53K
|
Process Industries
|
| O: -0.55%
H: 0.0%
C: 0.0%
treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.